Welcome to our dedicated page for Unity Biotechnology SEC filings (Ticker: UNBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Unity Biotechnology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Unity Biotechnology's regulatory disclosures and financial reporting.
Unity Biotechnology, Inc. received an amended Schedule 13G/A (Amendment No. 4) from ARCH-affiliated entities and managers stating they beneficially own 0 shares and represent 0% of the common stock (CUSIP 91381U200). The date of the event requiring the filing is 09/30/2025.
Each reporting person—ARCH Venture Fund VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; related ARCH Venture Partners entities; and individuals Keith Crandell, Robert Nelsen, and Clinton Bybee—reports 0 sole/shared voting power and 0 sole/shared dispositive power.
Unity Biotechnology, Inc. submitted a Certificate of Dissolution for the company that is effective September 26, 2025, and executed a Lease Termination Agreement and Amendment with Bayside Area Development, LLC dated September 24, 2025. The filing also references an interactive XBRL cover page and is signed by Craig Jalbert, President. These actions indicate formal steps to dissolve the corporate entity and to end at least one lease arrangement in late September 2025.
The document contains core corporate-closeout actions but no financial statements, forward guidance, or details about creditor claims, asset transfers, or shareholder distributions. There is insufficient transactional or financial detail in this filing to assess impacts on creditors, investors, or ongoing contractual obligations beyond the cited lease termination and the effective dissolution date.
Unity Biotechnology, Inc. held a special stockholder meeting where investors approved a proposal authorizing a potential corporate dissolution and an adjournment proposal related to that meeting. The voting power present represented 600,944,604 votes, or 97.36% of the outstanding voting power entitled to vote.
Stockholders approved the Dissolution Proposal by 450,228,768 votes for and 150,685,568 against, with 30,268 abstentions. A separate Adjournment Proposal was also approved. The Board now has discretion to determine the timing of filing a Certificate of Dissolution, to proceed with, amend, or abandon the dissolution under Delaware law.
The company warns that trading in its securities is highly speculative and risky, and that trading prices may bear little or no relationship to any value ultimately realized by security holders.